SCHEMBL30774496

SCHEMBL30774496

N#Cc1ccc(-c2cncc3c2CCN3C(=O)Cc2cccc(Cl)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 3/20 0.45
▸ EIF2AK2 P19525 1/20 0.45
▸ EIF2AK1 Q9BQI3 1/20 0.45
▸ EIF2AK3 Q9NZJ5 1/20 0.45
▸ UCHL1 P09936 2/20 0.43
▸ USP30 Q70CQ3 2/20 0.43
▸ CYP11B2 P19099 9/20 0.41
▸ CYP11B1 P15538 6/20 0.41
▸ FNTA P49354 1/20 0.40
▸ FNTB P49356 1/20 0.40
▸ PTPN11 Q06124 1/20 0.39
▸ EGLN2 Q96KS0 1/20 0.38
▸ PDCD1 Q15116 1/20 0.37
▸ CD274 Q9NZQ7 1/20 0.37
▸ SLC22A12 Q96S37 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30774383 0.89 RIPK1 (0.46) RIPK1EIF2AK3UCHL1USP30CYP11B2
SCHEMBL30774460 0.89 CYP11B2 (0.44) RIPK1UCHL1USP30CYP11B2CYP11B1
SCHEMBL30774488 0.87 RIPK1 (0.48) RIPK1EIF2AK2EIF2AK1EIF2AK3UCHL1
SCHEMBL30774584 0.86 RIPK1 (0.48) RIPK1EIF2AK2EIF2AK1EIF2AK3UCHL1
SCHEMBL30774028 0.85 NAAA (0.40) RIPK1EIF2AK2EIF2AK1EIF2AK3UCHL1
SCHEMBL30774494 0.84 UCHL1 (0.47) UCHL1USP30CYP11B2FNTAFNTB
SCHEMBL30774527 0.83 CYP11B2 (0.44) EIF2AK3UCHL1USP30CYP11B2CYP11B1
SCHEMBL30774574 0.83 CYP11B2 (0.44) EIF2AK3UCHL1USP30CYP11B2CYP11B1
SCHEMBL30774510 0.83 CYP11B2 (0.44) RIPK1UCHL1USP30CYP11B2CYP11B1
SCHEMBL30774465 0.82 CYP11B2 (0.46) UCHL1USP30CYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US claimed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP claimed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 RIPK1 3331/4885EIF2AK2 1624/4885EIF2AK1 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback